NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments
NervGen will restate its audited annual financials for the year ended December 31, 2025 and its unaudited interims for the quarter ended June 30, 2026, revising the valuation of certain warrants and options. The adjustments are non-cash and are expected to reduce previously reported stock-based compensation expense, warrant liabilities, and accumulated deficit.
Key figures
- Restatement nature
- non-cash; reduces stock-based compensation expense, warrant liabilities, and accumulated deficit
- Restatement periods
- ["FY ended December 31, 2025 (audited)","quarter ended June 30, 2026 (unaudited)","restated 2024 comparatives","January 1, 2024 opening balances"]
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.